Drug intelligence / Profile preview

Qβ-Aβ1-9

Development stage: Preclinical
Lead developer: Novartis
Modality: Vaccines & Immunotherapeutics
Administration: Parenteral

Overview

Qβ-Aβ1-9 is an experimental active **amyloid-beta immunotherapy vaccine** for Alzheimer's disease. It consists of the N-terminal amyloid-beta 1-9 peptide displayed in a dense repetitive array on a bacteriophage Qβ virus-like particle carrier. In APP transgenic mice, vaccination induced anti-amyloid-beta antibodies without an added adjuvant, generated weak or negligible amyloid-beta-specific T-cell responses, and reduced amyloid deposition. The published evidence is preclinical and no INN, marketed brand, or clinical development program for this exact construct was identified. ([europepmc.org](https://europepmc.org/article/MED/20066498))

Other names: Qβ-Aβ1-9

Targets

Aβ N-terminus (Amyloid beta peptide N-terminal epitope)

Beyond the preview

Go deeper on Qβ-Aβ1-9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qβ-Aβ1-9.

Explore the full profile